EVOTEC (ETR:EVT) target price raised to 5.40EUR, reported today by Bankhaus Lampe KG
- Updated: September 18, 2016
Yesterday EVOTEC (ETR:EVT) traded 0.98% lower at 4.38EUR. The company’s 50-day average is 20.84EUR and its two hundred day moving average is 20.03EUR. The last stock price is down 0.64% relative to the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. 108,980 shares of EVOTEC traded hands, down from ann avg. trading volume of 147,940.
In a report announced on 8/15/2016 Bankhaus Lampe KG increased the target price of EVOTEC (ETR:EVT) from 0EUR to 5EUR indicating a possible upsideof 0.23%.
Previously on 8/14/2016, Bankhaus Lampe KG reported on EVOTEC(ETR:EVT) upped the target price from 0.00EUR to 5.40EUR. At the time, this suggested an upside of 0.23%.
Recent Performance Graph:
EVOTEC has a 52 week low of 16.37EUR and a 52 week high of 21.25EUR. EVT’s market capitalization is currently 0.0 EUR.
About EVOTEC (ETR:EVT)
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), and an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.